Calithera Biosciences Long Term Debt

As of the most recent data (December 2022), CALA shows a long-term debt of $140K. That compares with $1.7M in the prior-year period — down 91.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CALA's long-term debt is now $140K (was $1.7M) — a 91.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Calithera Biosciences is outperforming or lagging.

Tracking CALA's long-term debt over time shows whether Calithera Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $140K That compares with $1.7M in the prior-year period — down 91.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Calithera Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $140K) with ownership activity and broader fundamentals.

Calithera Biosciences's long-term debt is $140K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.